The lack of robust BPC-157 human trialsspecifically Phase II and Phase III studiesmeans that definitive conclusions about its efficacy, optimal dosing, and long-term safety in humans cannot be made
Peptides should not replace diagnosis, rehabilitation, progressive loading, mobility work, strength training, or appropriate medical care
This conformational constraint is the key structural feature that distinguishes MT-2s pharmacology from the linear MSH analogues
Patients can ask questions, talk through concerns, and feel supported by someone who understands both the medical side of care and the community she serves
[DOI] [PubMed] [Google Scholar] 73.Cesarec V., Becejac T., Misic M., Djakovic Z., Olujic D., Drmic D., Brcic L., Rokotov D., Seiwerth S., Sikiric P
Altered striatal synaptic function and abnormal behaviour in Shank3 Exon4-9 deletion mouse model of autism